Skip to main content

Table 2 Model parameter values

From: Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis

Parameter Value References
\(Ag_{0}\) (nmol) 14.95 Assuming 90% of 1 kg (1012) antigen-positie cells are in the distribution volume, \(V_{d}\)
\(V_{d}\) (L) 3.8 [13]
\(k_{ + }\) (M−1 h−1) 0.5 [13]
\(k_{ - }\) (h−1) 0.003 [13]
\(T_{c}\) (h) 40 [13]
\(T_{i}\) (h) 0.5 Estimated
\(T_{ci}\) (h) 100 Estimated
\(f_{L1} ,f_{S1}\) 0.18, 0.12 [13]
\(f_{L2} ,f_{S2}\) 0.08, 0.06 [13]
\(V_{RMECF} ,V_{d}\) (L) 0.22, 3.8 [13]
\(f_{Ac227}\) 0.007 Based on EOB fraction and assuming two 225Ac half-lives until time to injection
\(f_{Ab}\) 0.7 Estimated